当前位置： SCI文献检索 > JOURNAL OF NEUROLOGY期刊下所有文献 > Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study.

Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study.

Abstract：

RATIONALE:Phase I/II studies of autologous hematopoietic stem cell transplantation (HSCT) for multiple sclerosis ( MS) were initiated, based on results of experimental transplantation in animal models of multiple sclerosis and clinical observations in patients treated concomitantly for malignant disease. PATIENTS:Eighty-five patients with progressive MS were treated with autologous HSCT in 20 centers and reported to the autoimmune disease working party of the European Group for Blood and Marrow Transplantation (EBMT). 52 (61 %) were female, median age was 39 [20-58] years. The median interval from diagnosis to transplant was 7 [1-26] years. Patients suffered from severe disease with a median EDSS score of 6.5 [4.5-8.5]. Active disease prior to transplant was documented in 79 of 82 evaluable cases. RESULTS:The stem cell source was bone marrow in 6 and peripheral blood in 79, and stem cells were mobilized into peripheral blood using either cyclophosphamide combined with growth factors or growth factors alone. Three patients experienced transient neurological complications during the mobilization phase. The high dose regimen included combination chemotherapy, with or without anti-lymphocyte antibodies or, with or without, total body irradiation. The stem cell transplants were purged of lymphocytes in 52 patients. Median follow-up was 16 [3-59] months. There were 7 deaths, 5 due to toxicity and infectious complications, 2 with neurological deterioration. The risk of death of any cause at 3 years was 10 (+/-7)% (95 % confidence interval). Neurological deterioration during transplant was observed in 22 patients; this was transient in most but was associated with MS progression in 6 patients. Neurological improvement by > or = 1 point in the EDSS score was seen in 18 (21 %) patients. Confirmed progression-free survival was 74 (+/-12)% at 3 years being 66 (+/-23)% in patients with primary progressive MS but higher in patients with secondary progressive or relapsing-remitting MS, 78 (+/-13)%; p = 0.59. The probability of confirmed disease progression was 20 (+/-11)%. MRI data were available in 78 patients before transplant showing disease activity (gadolinium enhancing, new or enlarging lesions) in 33 %. Posttransplant MRI showed activity at any time in 5/61 (8 %) evaluable cases. CONCLUSION:Autologous HSCT suggest positive early results in the management of progressive MS and is feasible. These multicentre data suggest an association with significant mortality risks especially in some patient groups and are being utilised in the planning of future trials to reduce transplant related mortality.

journal_name

J Neurol

journal_title

Journal of neurology

authors

Fassas A,Passweg JR,Anagnostopoulos A,Kazis A,Kozak T,Havrdova E,Carreras E,Graus F,Kashyap A,Openshaw H,Schipperus M,Deconinck E,Mancardi G,Marmont A,Hansz J,Rabusin M,Zuazu Nagore FJ,Besalduch J,Dentamaro T,Fouill

doi

10.1007/s00415-002-0800-7

keywords:

subject

Has Abstract

pub_date

2002-08-01 00:00:00

pages

1088-97

issue

eissn

0340-5354

issn

1432-1459

journal_volume

249

pub_type

临床试验,杂志文章,多中心研究

在线工具

Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study.